Agena Bioscience’s MassARRAY® System Excels in China Ministry of Health Comparison Study of KRAS Somatic Mutation Detection Methods

contributed by Agena Bioscience | 11/27/2017

Lianxing Yang, Ph.D. and Darryl Irwin*, Ph.D., Agena Bioscience
*Corresponding author: [email protected]

Many laboratories in China are running KRAS mutation detection assays to guide therapy selection for cancer treatment. To promote clinical KRAS mutation detection and improve the quality of laboratory testing, the National Center for Clinical Laboratories (NCCL) of the China Ministry of Health launched a KRAS External Quality Assessment project in 2014. In preparation for the project, the NCCL conducted a preliminary National KRAS Mutation Detection Inter-Lab Quality Evaluation Survey in 2013.

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Retina field I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.